These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37827841)

  • 1. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with
    Watabe T; Kabayama K; Naka S; Yamamoto R; Kaneda K; Serada S; Ooe K; Toyoshima A; Wang Y; Haba H; Kurimoto K; Kobayashi T; Shimosegawa E; Tomiyama N; Fukase K; Naka T
    J Nucl Med; 2023 Dec; 64(12):1949-1955. PubMed ID: 37827841
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
    Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
    [No Abstract]   [Full Text] [Related]  

  • 3. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
    Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma.
    Li M; Wei W; Barnhart TE; Jiang D; Cao T; Fan K; Engle JW; Liu J; Chen W; Cai W
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2737-2748. PubMed ID: 33537836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
    Kong Y; Xie F; Zhang Z; Wang S; Zhang Y; Di Y; Zhou Z; Jiang D; Li J; Huang Q; Wang J; Li X; Pan Z; Ni R; Guan Y
    Eur Radiol; 2023 Oct; 33(10):7077-7088. PubMed ID: 37166496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
    Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
    PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cadherin-17 as a target for the immunoPET of adenocarcinoma.
    Delaney S; Keinänen O; Lam D; Wolfe AL; Hamakubo T; Zeglis BM
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2547-2557. PubMed ID: 38625402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma.
    Harada E; Serada S; Fujimoto M; Takahashi Y; Takahashi T; Hara H; Nakatsuka R; Sugase T; Nishigaki T; Saito Y; Hiramatsu K; Nojima S; Mitsuo R; Ohkawara T; Morii E; Mori M; Doki Y; Kaneda Y; Naka T
    Oncotarget; 2017 Apr; 8(15):24741-24752. PubMed ID: 28445969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 targeted delivery of
    Labadie KP; Ludwig AD; Lehnert AL; Hamlin DK; Kenoyer AL; Sullivan KM; Daniel SK; Mihailovic TN; Sham JG; Orozco JJ; Yeung RS; Chen DL; Wilbur DS; Miyaoka RS; Park JO
    Sci Rep; 2021 Feb; 11(1):3731. PubMed ID: 33580090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oridonin-loaded and GPC1-targeted gold nanoparticles for multimodal imaging and therapy in pancreatic cancer.
    Qiu W; Chen R; Chen X; Zhang H; Song L; Cui W; Zhang J; Ye D; Zhang Y; Wang Z
    Int J Nanomedicine; 2018; 13():6809-6827. PubMed ID: 30425490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
    Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
    J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-particulate Toll-like Receptor 9 Agonist Potentiates the Antitumor Activity of Anti-Glypican-1 Antibody.
    Saito Y; Takahashi T; Hiramatsu K; Serada S; Fujimoto M; Ohkawara T; Sugase T; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Yamasaki M; Ishii KJ; Eguchi H; Doki Y; Naka T
    Anticancer Res; 2023 Jun; 43(6):2425-2432. PubMed ID: 37247902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Biodistribution of
    Ghosh S; Fletcher NL; Huda P; Houston ZH; Howard CB; Lund ME; Lu Y; Campbell DH; Walsh BJ; Thurecht KJ
    Mol Pharm; 2023 Mar; 20(3):1549-1563. PubMed ID: 36602058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
    Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
    J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
    Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.
    Busato D; Capolla S; Durigutto P; Mossenta M; Bozzer S; Sblattero D; Macor P; Dal Bo M; Toffoli G
    J Transl Med; 2023 Nov; 21(1):864. PubMed ID: 38017492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
    Fayn S; King AP; Gutsche NT; Duan Z; Buffington J; Olkowski CP; Fu Y; Hong J; Sail D; Baidoo KE; Swenson RE; Cheloha RW; Ho M; Choyke PL; Escorcia FE
    J Nucl Med; 2023 Jul; 64(7):1017-1023. PubMed ID: 36997331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma.
    Kayed H; Kleeff J; Keleg S; Jiang X; Penzel R; Giese T; Zentgraf H; Büchler MW; Korc M; Friess H
    Int J Oncol; 2006 Nov; 29(5):1139-48. PubMed ID: 17016645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.